2-cyclohexyl-N,N-dimethylethanamine | 2358-91-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-cyclohexyl-N,N-dimethylethanamine
• 英文别名: N.N-Dimethylcyclohexylethylamin；(2-cyclohexyl-ethyl)-dimethyl-amine；(2-Cyclohexyl-aethyl)-dimethyl-amin；2-Dimethylamino-1-cyclohexyl-aethan；2-cyclohexyl-(N,N-dimethylamino)-ethan；2-cyclohexyl-N,N-dimethylethylamine；N,N-dimethyl-2-cyclohexylethylamine；InChI=1/C10H21N/c1-11(2)9-8-10-6-4-3-5-7-10/h10H,3-9H2,1-2H
• CAS: 2358-91-0
• 化学式: C₁₀H₂₁N
• 分子量: 155.283
• InChiKey: VXLIXPQRVBTYGB-UHFFFAOYSA-N

物化性质

• 沸点：
  83 °C(Press: 15 Torr)
• 密度：
  0.842±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-cyclohexyl-N,N-dimethylethanamine 生成 (2-cyclohexyl-ethyl)-trimethyl-ammonium; iodide
  参考文献：
  名称：

  72.还原环状碱基的合成和立体化学研究。第一部分。吲哚的氢化产物和N-甲基八氢吲哚的详尽甲基化

  摘要：

  DOI：

  10.1039/jr9450000277
• 作为产物：
  描述：

  N,N-二甲基-2-苯乙胺 在 甲醇 、 镍 作用下， 200.0 ℃ 、7.84 MPa 条件下， 生成 2-cyclohexyl-N,N-dimethylethanamine
  参考文献：
  名称：

  72.还原环状碱基的合成和立体化学研究。第一部分。吲哚的氢化产物和N-甲基八氢吲哚的详尽甲基化

  摘要：

  DOI：

  10.1039/jr9450000277

文献信息

• Dimethylamination of Primary Alcohols Using a Homogeneous Iridium Catalyst: A Synthetic Method for <i>N</i>,<i>N</i>-Dimethylamine Derivatives
  作者：Jaeyoung Jeong、Ken-ichi Fujita

  DOI：10.1021/acs.joc.0c02896

  日期：2021.3.5

  alcohols using aqueous dimethylamine in the absence of additional organic solvents has been developed. The reaction proceeds via borrowing hydrogen processes, which are atom-efficient and environmentally benign. An iridium catalyst bearing an N-heterocyclic carbene (NHC) ligand exhibited high performance, without showing any deactivation under aqueous conditions. In addition, valuable N,N-dimethylamine

  已经开发了在不存在其他有机溶剂的情况下使用二甲胺水溶液进行伯醇的N，N-二甲基氨基化的新催化系统。该反应通过借用氢过程进行，该过程是原子有效的且对环境无害。带有N-杂环卡宾（NHC）配体的铱催化剂表现出高性能，而在水性条件下没有任何失活。另外，合成了有价值的N，N-二甲基胺衍生物，包括生物活性分子和药物分子。这种方法的实际应用已通过克级反应得到了证明。
• 8-OXODIHYDROPURINE DERIVATIVE
  申请人：Aachi Keiji

  公开号：US20120172347A1

  公开（公告）日：2012-07-05

  The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like.

  本发明提供一种由式（1）表示的化合物或其药用可接受的盐（其中W代表氢原子、卤素原子或其他；A代表可选地被芳基取代的烷基基团或其他、芳基团或其他；X和Y中的一个代表二取代的烷基氨基羰基团或其他，另一个代表氢原子、烷基基团、烷基羰基团或其他）；一种治疗或预防FAAH相关疾病如抑郁症、焦虑症或疼痛的药物或药物组合物，包括该化合物或类似物作为活性成分；一种使用该化合物或类似物的用途；以及使用该化合物或类似物的治疗或预防方法。
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• [EN] QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME<br/>[FR] DÉRIVÉS DE QUINOLINE ET INHIBITEURS DE MELK LES CONTENANT
  申请人：ONCOTHERAPY SCIENCE INC

  公开号：WO2012016082A1

  公开（公告）日：2012-02-02

  The present invention directs a compound represented by formula (I).

  本发明涉及一种由化学式（I）表示的化合物。
• Aromatic Compounds
  申请人：Fukushima Tae

  公开号：US20070270422A1

  公开（公告）日：2007-11-22

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，具有抑制胶原生成的优异效果，并且具有较少的副作用，在安全性方面表现出色。本发明的化合物由以下通式（1）表示：[其中X1代表氮原子或基团—CH═；R1代表基团-Z-R6，其中Z代表基团—CO—、基团—CH(OH)—或类似基团，而R6代表具有1到4个氮原子、氧原子或硫原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团；R2代表氢原子、卤素原子或低碳链基团；Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团；A代表基团或类似基团，其中R3代表氢原子、低碳醚基团或类似基团，p代表1或2，而R4代表咪唑基低碳基团或类似基团。

表征谱图